Early identification of haemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 1, 2009, Pages 48-60

  Sharma, P ^a,b,c   Kumar, A ^b,c   Sharma, B C ^b   Sarin, S K ^b,c  

^a UNIVERSITY OF DELHI   (India)

^b G B PANT HOSPITAL   (India)

^c INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE 5 NITRATE; PROPRANOLOL; SOMATOSTATIN; TERLIPRESSIN;

ABDOMINAL PRESSURE; ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS VARICES BLEEDING; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART RATE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; PULSE RATE; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HUMANS; ISOSORBIDE DINITRATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPRANOLOL; RISK FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 67449101797     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04015.x     Document Type: Article

References (29)

1. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002 122 : 1620 30.
2. D'Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003 38 : 599 612. (Pubitemid 37052147)
3. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004 40 : 652 9.
4. Tiani C, Abraldes JG, Bosch J. Portal hypertension: pre-primary and primary prophylaxis of variceal bleeding. Dig Liver Dis 2008 40 : 318 27.
5. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005 43 : 167 76.
6. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007 46 : 922 38.
7. Sarin SK, Kumar A, Angus PW, et al. Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver. Hepatol Int 2008 1 : 398 413.
8. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999 19 : 475 505. (Pubitemid 30032646)
9. García-Pagán JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991 114 : 869 73.
10. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996 348 : 1677 81.
11. Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000 31 : 324 9.
12. García-Pagán JC, Morillas R, Bañares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003 37 : 1260 6.
13. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990 99 : 1401 7.
14. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000 32 : 930 4.
15. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006 101 : 506 12.
16. Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol 2003 98 : 2742 50.
17. Hicken BL, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 2003 17 : 145 53.
18. Bureau C, Péron JM, Alric L, et al. "A La Carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002 36 : 1361 6.
19. Conn HO. Ammonia tolerance in the diagnosis of esophageal varices. A comparison of endoscopic, radiologic, and biochemical techniques. J Lab Clin Med 1967 70 : 442 51.
20. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004 39 : 280 2.
21. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999 160 : 535 41.
22. Merkel C. Nonselective beta-blockers plus nitrates in portal hypertension: an open question. Hepatology 2003 37 : 1254 6.
23. Bosch J. A la carte or menu fixe: improving pharmacologic therapy of portal hypertension. Hepatology 2002 36 : 1330 2.
24. Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007 102 : 2842 8.
25. Garcia-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990 11 : 230 8.
26. Silva G, Segovia R, Ponce R, et al. Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis. Hepatogastroenterology 2002 49 : 1357 62.
27. Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G, Zuin R. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J 1984 108 : 1167 72.
28. Bañares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002 36 : 1367 73.
29. González-Abraldes J, Albillos A, Bañares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001 121 : 382 8.